Abstract
With COVID-19 N95 respirator shortages, frontline medical personnel are forced to reuse this disposable – but sophisticated – multilayer textile respirator. Widely used for decontamination of nonporous surfaces, UV-C light has germicidal efficacy on porous, non-planar N95 respirators when ≥1.0 J/cm2 dose is applied across all surfaces. Here, we address outstanding limitations of photochromic indicators (qualitative readout and insufficient dynamic range) and introduce a photochromic UV-C dose quantification technique for: (1) design of UV-C treatments and (2) in-process UV-C dose validation. Our methodology establishes that color-changing dosimetry can achieve the necessary accuracy (>90%), uncertainty (<10%), and UV-C specificity (>95%). Furthermore, we adapt consumer electronics for accessible quantitative readout and extend the dynamic range >10× using optical attenuators. In a measurement infeasible with radiometers, we observe striking 20× dose variation over 3D N95 facepieces. By transforming photochromic indicators into quantitative dosimeters, we illuminate critical design considerations for both photochromic indicators and UV-C decontamination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
No clinical trials involved.
Funding Statement
We gratefully acknowledge funding support from the University of California, Berkeley College of Engineering Dean's COVID-19 Emergency Research Fund, NIH training grant under award #T32GM008155 (A. Su and A. Geldert), National Science Foundation Research Fellowship Award #DGE 1106400 (A. Su), National Defense Science and Engineering Graduate (NDSEG) Fellowship (A. Geldert), the Natural Sciences and Engineering Research Council of Canada (NSERC) postdoctoral fellowship (PDF, to S.M. Grist. and postgraduate scholarship (PGS-D 487496, to A. Gopal), and the Chan Zuckerberg Biohub Investigator Program (PI: A.E. Herr). We are grateful for the generosity of Spectroline, Intellego, UV Process Supply, and Precision Glass and Optics in providing critical materials and samples for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All reported data are available from the corresponding author upon reasonable request.
